Clinical Trial Update: PD 0332991 and Cetuximab in Patients With Incurable SCCHN [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating PD-0332991 (palbociclib) with cetuximab in patients with incurable squamous cell carcinoma of the head and neck has completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Cetuximab (cetuximab)
• PD 0332991 (palbociclib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Carcinoma, Squamous Cell of Head and Neck | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-06-11